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Summary
PURPOSE: Extra-abdominal desmoid tumours are benign
and rare, and lead to a persistent treatment dilemma be-
cause of their high recurrence rate and their heteroge-
neous behaviour. The goal of this retrospective study was
to evaluate the results of different treatment modalities for
extra-abdominal desmoid tumours at four sarcoma treat-
ment centres.
METHODS: The mean follow-up time for the 96 patients
included in the study (63.5% female; mean age 38.9
years) was 8.4 years (2.0–40.5 years). The initial treat-
ments were surgery (n = 44), surgery with radiation (n
= 16), watchful waiting (n = 15), radiation only (n = 9),
or systemic treatment (n = 12). Patient demographics, tu-
mour sites, and the follow-up status of all patients were re-
viewed and evaluated for each of the treatment modalities.
RESULTS: The local recurrence rate was 45.5% in pa-
tients with primary surgical treatment and 37.5% following
surgery combined with irradiation. Patients who were
treated with radiation alone showed regressive (33.3%)
or stable disease (66.6%). Systemic treatment alone re-
sulted in disease progression in 41.7% of our patients.
In the watchful waiting group, 73.3% showed stable dis-
ease, 20.0% showed spontaneous regression, and 6.7%
showed progression after a mean follow-up of 4.1 years
(2.0–11.5 years).
CONCLUSIONS: Our results suggest that a watchful wait-
ing approach should be the first line treatment in asymp-
tomatic desmoid tumours. However, radiation can help im-
prove local control rates in patients who have undergone
surgery. Progression and local recurrence rates following
systemic treatment were comparable to those observed in
surgery combined with radiation.
Keywords: desmoid tumour, watchful waiting, sarcoma,
regression, progression
Introduction
Desmoid tumours are rare and histologically benign but
locally aggressive neoplasms characterised by infiltrative
growth and a tendency towards local recurrence [1].
The pathophysiology of these tumours is not yet fully un-
derstood. Genetic, endocrine and physical factors play a
role in their development and growth [2]. Growth factors
expressed as a result of trauma (including surgery) may
contribute to growth and/or recurrence [3].
Desmoid tumours mainly affect individuals between 10
and 40 years of age. Extra-abdominal desmoid tumours
arise in the extremities, head, neck and trunk, and the tho-
racic and abdominal walls [1, 4, 5]. Spontaneous regres-
sion may also be observed [4, 5]. Considering the wide
variation in clinical presentation and the unpredictable nat-
ural history of the disease, an individualised treatment ap-
proach and interdisciplinary input from a tumour centre are
recommended [6].
Desmoid tumours create a treatment dilemma. In the past,
wide or radical local excision was the most common treat-
ment. However, the risk of recurrence was high (>40%)
[7–11]. Furthermore, the extent of the correlation between
positive margins and recurrence is controversial [6,
12–14]. Finally, there is a paucity of good data on the nat-
ural history of the disease with, or especially without treat-
ment [9].
The aim of this study was to estimate the recurrence rates
in patients diagnosed with extra-abdominal desmoid tu-
mours according to treatment modality. The primary out-
come was the recurrence rate of desmoid tumours. In pa-
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tients who did not undergo tumour removal, disease
progression was assessed.
Materials and methods
We retrospectively enrolled 96 patients (61 female, 35
male) diagnosed with extra-abdominal desmoid tumours at
the Sarcoma Centres of Basel, Bern, Zurich or Lausanne.
The study was approved by the Ethics Committees of
Northwest and Central Switzerland (approval 2014/172).
The committee waived the need to obtain written informed
consent from all patients. Inclusion criteria were follow-up
of at least 24 months and age at diagnosis of ≥16 years.
Exclusion criteria were intra-abdominal desmoid tumours,
retroperitoneal tumours and patients with incomplete data
(n = 24 patients).
Initial and subsequent treatment, follow-up status with re-
currence rates, and time to an event were recorded for five
different treatment modalities. Final follow-up status was
defined as recurrence of the desmoid tumour versus no evi-
dence of disease. In patients treated non-surgically, disease
progression was considered as “recurrence”. The five treat-
ment modalities were surgery without radiation (n = 44),
surgery with radiation (n = 16), radiation without surgery
(n = 9), systemic treatment (n = 12), and watchful wait-
ing (n = 15). In the case of watchful waiting, no treatment
commenced unless disease progression was observed.
All histological diagnoses were made and/or confirmed by
a reference pathologist at one of the sarcoma centres (DB,
BB).
Recurrence was analysed using Cox proportional hazards
models, implementing Firth’s penalised likelihood bias re-
duction due to the low number of events in some of the
groups [15, 16]. Kaplan-Meier curves were used to show
the recurrence over time. Patients without recurrence were
censored at their last follow-up. The time to an event for
each patient started on the date of the first treatment. In pa-
tients with no active treatment (i.e., watchful waiting), the
time started on the date of diagnosis. Only the ﬁrst recur-
rence was considered as an endpoint in our analysis. Fur-
ther treatments and recurrences were ignored.
The watchful waiting group was used as the reference
group. First, the watchful waiting group was compared
to the largest groups, those of surgery or surgery with
radiation patients. Secondly, the association between tu-
mour location and recurrence rate was examined in surgery
(or surgery with radiation) patients. Finally, in patients
who underwent active treatment (i.e., not watchful wait-
ing), rate of recurrence was compared between radiation
patients and patients who had received other treatments
(surgery, surgery + radiation or systemic).
Descriptive statistics were used to summarise demograph-
ics and baseline patient data. Comparisons of baseline val-
ues between patients who suffered recurrence and those
who did not were based on Wilcoxon’s rank-sum test for
continuous variables and Fisher’s exact test for categorical
variables.
All analyses were performed using R, version 3.3.1. A p
value <0.05 was considered significant.
Results
Baseline characteristics are summarised in table 1. Mean
age at diagnosis was 38.9 years and median follow-up was
8.4 years (range 2.0–44.5 years). At the last follow-up,
92 patients (95.8%) were alive and 4 patients (4.2%) had
died for unrelated reasons. Age at diagnosis was a signif-
icant factor for recurrence: recurrence was more frequent-
ly seen in younger patients (p = 0.028). The median fol-
low-up time in patients without recurrence was 4.6 years
(range 1.8–37 years). A summary of the follow-up times
for groups without recurrence is given in table 2.
In cases with surgery (with or without radiation, n = 46),
resection margins were wide in 16 patients, marginal in 24
patients, and intralesional in 6 patients. Of the 16 patients
treated with both surgery and radiation, the dose was un-
known in 5 cases; the other 11 (68.8%) received a median
dose of 54 Gy (range 25–60 Gy). Patients treated with ra-
diation only received a median dose of 52 Gy (range 46–60
Gy). The dose was unknown in two cases.
Eight out of the 12 patients who received systemic treat-
ment (t) received tamoxifen only. Three patients received
Table 1: Summary of patient data.
Overall No recurrence Recurrence p-value
No. 96 62 34
Sex = female, n (%) 61 (63.5) 36 (58.1) 25 (73.5) 0.184
Age at diagnosis, median (IQR) 36.5 (27.8–49.0) 40.00 (29.25–53.50) 32.00 (25.00–42.50) 0.028
Site, n (%) Abdomen 16 (16.7) 13 (21.0) 3 (8.8) 0.184
Extremities 45 (46.9) 28 (45.2) 17 (50.0)
Pelvis 7 (7.3) 3 (4.8) 4 (11.8)
Thoracic wall 10 (10.4) 7 (11.3) 3 (8.8)
Trunk 18 (18.8) 11 (17.7) 7 (20.6)
Diagnosis method, n
(%)
Computed tomography 9 (10.0) 4 (6.8) 5 (16.1) 0.343
Magnetic resonance imaging 78 (86.7) 53 (89.8) 25 (80.6)
Ultrasound 3 (3.3) 2 (3.4) 1 (3.2)
Beta-catenin = yes, n (%) 44 (88.0) 27 (84.4) 17 (94.4) 0.399
Treatment, n (%) Watchful waiting 15 (15.6) 12 (19.4) 3 (8.8) 0.053
Radiation alone 9 (9.4) 9 (14.5) 0 (0.0)
Surgery alone 44 (45.8) 24 (38.7) 20 (58.8)
Surgery and radiation 16 (16.7) 10 (16.1) 6 (17.6)
Systemic treatment 12 (12.5) 7 (11.3) 5 (14.7)
IQR = interquartile range Comparison between patients with and without recurrence using Fisher’s exact test for categorical variables and Wilcoxon’s rank-sum test for continuous
variables.
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tamoxifen in combination with celecoxib and sulindac. In
one case, a combination of methotrexate and vinblastine
was administered.
Local recurrence occurred in 34 patients (35.4%), and 62
patients (64.6%) showed no recurrence or progression. The
time to recurrence varied from 2 months to 6.4 years. In
patients with recurrence or progression after non-surgi-
cal treatment, 44.1% (15 out of 34) had more than one
recurrence. No recurrences (or disease progression) were
recorded in the radiation group. Results with regards to re-
currence for the different treatment modalities are shown
in figure 1. The overall recurrence rate was <50%.
Hazard ratios (HRs) for recurrence show that with the ex-
ception of the radiation group, the HRs for all other groups
were higher (>1) than that of the watchful waiting group
(table 3). The HR was lowest in the radiation group (no
events). None of these differences were statistically signiﬁ-
cant. The overall clinical observation times differed signiﬁ-
cantly between treatment groups (p <0.001).
The observation time was significantly shorter in the radi-
ation group compared to the surgery and surgery with radi-
ation groups (p = 0.005 and p = 0.078, respectively). Fur-
thermore, the observation time was shorter in the watchful
waiting group than in the surgery group (figs 1 and 2).
Figure 1: Kaplan-Meier curves for recurrence over all treatment
groups.ww = watchful waiting; r = radiation alone; s = surgery
alone; sr = surgery combined with radiation; t = systemic treatment
Tumour location was not a significant factor for recurrence
(p = 0.547). No signiﬁcant differences in the HR of recur-
rence were found between different tumour sites (HR 1.27,
95% conﬁdence interval [CI] 0.58–2.75).
Surgery
After primary surgery (n = 44), 45.4% (n = 20) of patients
developed recurrence, with a mean time to recurrence of
1.1 years (range 0.14-2.5). Thirty-seven patients with
known resection margins underwent surgery without radi-
ation. Recurrence occurred in 30.8% (n = 4) of patients
with wide resection (n = 13), compared to 50.0% (n = 10)
of those with marginal resection (n = 20) and 100.0% (n
= 4) of those with intralesional resection (n = 4). Resec-
tion margins were unknown in seven patients, and the re-
currence rate of these cases was 28.6% (n = 2). The re-
currence rate was significantly higher in the intralesional
resection group (p = 0.021). No significant difference was
recorded between patients with marginal and wide resec-
tion. The overall likelihood ratio of the effect of surgical
margins was not statistically signiﬁcant (p = 0.086) (fig. 3).
Figure 2: Boxplot shows that the observation time was shorter in
the radiation treatment group compared to the surgery and surgery
with radiation groups (marginally significant differences). The ob-
servation time in the watchful waiting group was shorter than in the
surgery group.ww = watchful waiting; r = radiation alone; s =
surgery alone; sr = surgery combined with radiation; t = systemic
treatment
Table 2: Follow-up times (years) in patients with no recurrence, by treatment group.
Minimum 1st quartile Median Mean 3rd Quartile Maximum
Watchful waiting 2.43 2.89 3.37 4.29 4.74 11.55
Radiation alone 1.88 2.21 3.25 3.29 4.60 4.96
Surgery alone 2.00 3.19 6.30 9.25 8.27 36.88
Surgery and radiation 2.98 4.66 6.22 10.29 11.44 36.91
Systemic treatment 1.98 2.98 7.60 6.66 9.20 12.66
Table 3: Analysis of recurrence rates for different treatment modalities according to treatment group
Treatment No recurrence Recurrence HR 95% CI p-value
Watchful waiting 12 (80.0) 3 (20.0) Reference
Radiation alone 9 (100.0) 0 (0.0) 0.23 0.00–2.39 0.252
Surgery alone 24 (54.5) 20 (45.5) 2.31 0.83–8.70 0.113
Surgery and radiation 10 (62.5) 6 (37.5) 1.56 0.44–6.58 0.495
Systemic treatment 7 (58.3) 5 (41.7) 1.93 0.51–8.37 0.328
Overall incidence (%) reported with hazard ratios (HR) and 95% confidence intervals (CI) calculated from a Cox-proportional hazard regression implementing Firth’s penalised
likelihood bias reduction due to the low number of events.
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Patients with recurrence (n = 20) received the following
additional treatments, with different re-recurrence rates
(RRR): 13 patients received surgery alone (RRR 69.2%, n
= 9), three patients received surgery plus radiation (RRR
33.3%, n = 1), three patients received radiation alone (RRR
33.3%, n = 1), and one patient was treated with tamoxifen
(RRR 100.0%, n = 1).
Surgery plus radiation
In the surgery with radiation group (n = 16), 37.5% (n = 6)
had recurrent desmoid tumours, with a mean time to recur-
rence of 3.1 years (range 0.88–5.8). Recurrence occurred
in 33.3% (n = 1) of patients with wide resection (n = 3),
compared to 36.4% (n = 4) of patients with marginal re-
section (n = 11) and 50.0% (n = 1) of patients with intrale-
sional resection (n = 2). One patient with marginal initial
Figure 3: Kaplan-Meier curves for recurrence comparing the differ-
ent surgical margins (). Table shows the overall incidence (%) re-
ported, with hazard ratios (HR) and 95% confidence intervals (CI)
calculated from a Cox-proportional hazard regression.w = wide; m
= marginal; i = intralesional
resection developed radiation-induced secondary sarcoma
after 12 years.
Patients with recurrences (n = 6) received the following ad-
ditional treatments, with different RRR: three patients re-
ceived surgery alone (RRR 0.0%, n = 0), two patients un-
derwent systemic treatment (tamoxifen and imatinib plus
sulindac, respectively; RRR 100%, n = 2), and one patient
had watchful waiting (RRR 100%, n = 1).
Radiation
All patients treated with radiation alone (n = 9) had regres-
sive (33.3%, n = 3) or stable (66.6%, n = 6) disease at the
last follow-up, with no progression reported.
A comparison of the recurrence rates of radiation patients
with the recurrence rates with all other treatment methods
except watchful waiting showed a signiﬁcant HR (HR
8.46, 95% CI 1.19–1071.58; p = 0.027).
Systemic treatment
In surgery patients (n = 12), 41.7% (n = 5) showed pro-
gression, 33.3% (n = 4) had stable disease, and 25.0% (n
= 3) showed regression. Mean time to progression was 2.5
years (range 0.67-6.4).
Patients with progression (n = 5) received the following
additional treatments, with different outcomes: one patient
underwent surgery with wide resection (no evidence of dis-
ease after 9.2 years), one patient underwent surgery with
intralesional resection (stable disease after 1.7 years), two
patients received radiation therapy (stable disease after 1.1
years and lost to follow-up), and one patient had systemic
treatment (stable disease after 4.2 years).
Watchful waiting
In watchful waiting patients (n = 15), 60.0% had stable dis-
ease (n = 9), 20.0% had spontaneous regression (n = 3; fig.
4), and 20.0% showed progression (n = 3). Mean follow-up
was 4.1 years (range 2.0–11.5) and mean time to progres-
sion was 1.2 years (range 0.9–1.5).
Figure 4: Example of spontaneous regression. An 18-year-old male athlete with a very large desmoid tumour located over the whole quadri-
ceps muscles of the right thigh (a) with severe pain and the request for surgery with significant functional impact. Before surgery, he fulfilled a
wish to ride his bike through Alaska, and the follow-up showed a significant decrease in the tumour size (b) and symptoms, removing the ne-
cessity for surgery.
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Patients with progression (n = 3) received the following
further treatments, with different outcomes: one patient un-
derwent surgery plus radiation (no evidence of disease af-
ter 4.0 years), and of the two patients for whom subsequent
treatment was unknown, one showed stable disease (after
1.6 years) and the other showed progression again (after
0.6 years).
Discussion
The aim of this study was to estimate the recurrence rates
in patients diagnosed with extra-abdominal desmoid tu-
mours according to treatment modality. Data beginning in
1970 were collected and patients were followed for vary-
ing time periods, up to >40 years. The primary outcome
was the recurrence/disease progression of the desmoid tu-
mour.
The results show an overall recurrence rate of 35.4% (34 of
96), which contrasts with previously reported local recur-
rence rates of 44-68% [10–14]. The rate of re-recurrence,
however, was 44.12% (15 of 34), within this range. The
shortest time to recurrence was two months, likely due to
incomplete resection.
We found no significant differences in the HR for recur-
rence between different tumour sites. Although location
was not identified as an independent prognostic factor,
outcomes did vary between different locations in another
study, which could be attributed to the close proximity to
vital structures and the difficulty of resection [17]. There
was a clear association between site and local recurrence-
free survival (LRFS) in a large study, with the best out-
come (5-year LRFS of 90%) for abdominal wall tumours,
followed by chest wall (72%), upper extremity (60%), low-
er extremity (47%), and desmoids of the neck (43%) [18].
Regarding the impact of surgical margins on recurrence
rates, a significant increase in HR was found for the in-
tralesional treatment group, whereas the difference in HR
between the marginal resection and wide resection groups
was not significant. This finding agrees with other reports,
which show a lack of any correlation between positive
margins and recurrence [9, 16–18]. Other studies with
more than 100 patients also reported a lack of correlation.
Thus, complete surgical clearance does not prevent recur-
rence, nor does incomplete resection necessarily lead to re-
currence. However, other results are contradictory, as the
impact of margins depends on a multitude of factors [6,
12–14].
Not all tumours recur. In fact, the observed spontaneous
stabilisation or occasional regression corresponds with
previous observations [7, 8].
No recurrences were observed in the radiation group (0 out
of 9). However, this result could be biased, given the low
number of patients. In addition, the follow-up time for ra-
diation patients was considerably shorter than for the pa-
tients on other treatment regimens (see fig. 2), and so re-
currences could have been missed.
Post-operative radiotherapy is an option for the treatment
of desmoid tumours, especially in patients with positive
margins after surgery, after recurrence, or for limb preser-
vation. Moreover, the recurrence rate was lower in the
surgery with radiation group than in the surgery group. Ra-
diotherapy can be a sufficient adjuvant treatment option
in patients with positive margins [15, 16]. The negative
side effects (e.g., secondary sarcomas) must be considered,
however, especially in young patients [16, 19]. One of our
patients developed a radiation-induced sarcoma following
treatment of a desmoid tumour.
Although the number of systemic treatment patients was
small and the results were not promising, chemotherapy
represents an efficient therapeutic option. Potential side ef-
fects of the secondary treatment must be considered, how-
ever [20].
Results for alternative systemic treatment options such as
anti-oestrogen therapy were encouraging, with 10/13 re-
sponding to tamoxifen + sulindac in familial adenomatous
polyposis-associated desmoid tumours, and 3/3 in sporadic
tumours [21].
Although the HR of recurrence / progression were general-
ly higher in all groups other than the radiation and watch-
ful waiting groups, none of the differences were statistical-
ly significant. The relatively small sample size and the low
event rate limited the study’s power to identify significant
effects. These biases could be overcome with a larger co-
hort, but this might be difficult within Switzerland because
of the low prevalence of desmoid tumours. Nevertheless,
the tendency towards low progression rates in the watch-
ful waiting group encourages a watchful waiting approach
with careful observation [4, 17]. This approach has been
recommended by others, who have shown progression-free
survival rates of 50% after five years [22–25].
Local recurrence of desmoid tumours is frequent, but has
been inconsistently associated with the adequacy of sur-
gical excision. Attempts to achieve tumour-free resection
margins may result in significant morbidity. Despite the
lack of metastatic potential, desmoid tumours may prove
fatal due to the local effects of growth, especially in the
head and neck. Because the timing of diagnosis is un-
known in relation to disease progression, an initial obser-
vation period may be considered in these patients, especial-
ly when surgery could result in significant loss of function.
Thus, quality of life should be the focus of treatment deci-
sions. Misunderstanding of the watchful waiting approach
can be avoided by detailed briefing of patients, as well as
by continuous care to avoid loss to follow-up [6]. A step-
wise consensus algorithm was proposed recently, based on
expertise from the sarcoma community, the European Or-
ganisation for Research and Treatment of Cancer’s Soft
Tissue and Bone Sarcoma Group, patients’ advocates from
Sarcoma Patients EuroNet, and available evidence [6].
This study has several limitations. It was retrospective, and
a lower level of evidence was accepted for clinical deci-
sion-making owing to the rarity and long natural histo-
ry of the disease. This leads to reduced statistical power
and to reduced estimate precision. Secondly, outcome mea-
sures were based on data collected at four different Swiss
Sarcoma Centres over the last 40 years, and the quality
of recordkeeping and decision-making has changed over
time. Moreover, the study cohort and follow-up times for
different treatment groups were heterogeneous. However,
the prevalence of desmoid tumours was low and – although
24 patients were excluded – a respectable number of pa-
tients were included in the analysis. Although limited, our
results support existing evidence that watchful waiting
should be followed for desmoid tumours.
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